Molecular Diagnosis of Systemic Autoinflammatory Diseases (SAIDiag)

Systemic autoinflammatory diseases (SAIDs) are a set of rare clinically and genetically heterogeneous conditions. The project proposes to identify novel genes and specific signatures in subgroups of patients with SAIDs.

Study Overview

• Status: Recruiting
• Conditions: Genetic Disease; Inflammatory Disease; Somatic Mutation; Molecular Sequence Variation; Molecular Pathway Deregulation

Detailed Description

SAIDs are characterized by long dormant periods with no or only minor clinical symptoms interrupted by febrile crises accompanied by serous and synovial membrane inflammation that spontaneously resolves. Over the last decades, more than 50 genes encoding key components of the innate immune system have been identified to be involved in the pathophysiology of SAIDs, with both germline and somatic mosaic variations. When disease-causing variations are identified, specific biotherapies are proposed depending on the involved gene and pathway. However, despite these scientific advances, most SAIDs (70%) are of unknown etiology, the diagnosis is made with significant delay, and no targeted therapy can be suggested. This project aims to generate specific understanding and develop strategies for SAID patients with unknown etiology. The investigators aim to advance our understanding of SAIDs pathophysiology, find the disease-causing gene variations and identify the involved cellular pathways that should accelerate correct diagnosis and personalize treatment.

• Study Type: Observational
• Enrollment (Estimated): 300

Contacts and Locations

• Study Contact: Name: Irina GIURGEA; Phone Number: +33144735295; Email: irina.giurgea@inserm.fr

Study Locations

• France
  • Paris, France, 75012
    • Recruiting
    • Trousseau Hospital
    • Contact: Irina GIURGEA, MD-PhD
    • Contact: Email: irina.giurgea@inserm.fr

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 1 week to 120 years (Child, Adult, Older Adult)
• Accepts Healthy Volunteers: Yes

• Sampling Method: Probability Sample

Study Population

Participants in this research will be recruited during a follow-up consultation for their condition.

Description

Inclusion Criteria:

• A patient presenting with a clinical and biological aseptic inflammatory syndrome associating one or more of the following signs: spontaneously resolving fever, abdominal (pain, diarrhea), locomotor (arthralgia, myalgia), thoracic (pain, pericarditis), cutaneous, sensory (uveitis, deafness), or renal (amyloidosis) involvement.

Exclusion Criteria:

• Adult subject to legal protection measures (guardianship, curatorship, safeguard of justice).

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
To identify SAIDs disease-causing mutations and genes and to explore specific biological signatures.	Molecular studies will be performed through the use of a SAID next generation sequencing (NGS) gene panel, followed by whole exome/genome sequencing (WES/WGS) in patients with no obvious genetic abnormality identified by the gene panel. When possible trio studies (the patient and his parents) will be performed in order to facilitate the interpretation of the molecular variants. Transcriptomics and cytokines profiles will be performed on whole blood cells to identify weakly expressed genes/proteins and by single cell experiments in order to assess cell-specific expression. These data will permit to better shape functional studies and to explore specific biological signatures.	Anytime in the period of 10 years
To identify novel and better assess the disease pathways	Functional studies will be performed to evaluate the pathogenicity of the identified molecular variants, to assess the involvement of new candidate genes in SAIDs, to characterize the molecular networks to which the corresponding proteins belong and to open up new therapeutic avenues.	Anytime in the period of 10 years

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
To propose personalized treatment options	Depending on the disease gene identified and on the involved signalling pathway, specific biotherapies could be proposed to SAID patients.	Anytime in the period of 10 years

Collaborators and Investigators

• Sponsor: Institut National de la Santé Et de la Recherche Médicale, France

Study record dates

Study Major Dates

• Study Start (Actual): May 18, 2022
• Primary Completion (Estimated): May 31, 2032
• Study Completion (Estimated): May 2, 2033

Study Registration Dates

• First Submitted: April 8, 2022
• First Submitted That Met QC Criteria: May 3, 2022
• First Posted (Actual): May 6, 2022

Study Record Updates

• Last Update Posted (Actual): January 31, 2024
• Last Update Submitted That Met QC Criteria: January 30, 2024
• Last Verified: January 1, 2024

More Information

Terms related to this study

• Keywords: Biomarkers
• Additional Relevant MeSH Terms: Genetic Diseases, Inborn
• Other Study ID Numbers: C20-97

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No